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Abstract
Inflammatory myositis is reported in 4-16% of adult systemic lupus erythematosus (SLE) patients. The aim of this
study was to determine the prevalence of myositis in a cohort of pediatric SLE patients in the southeastern United
States. A retrospective chart review was performed of 55 SLE patients evaluated by Pediatric Rheumatologists in
Alabama since January 1, 2008. Patients were defined as having myositis if they satisfied one of the following
categories: 1) Proximal muscle weakness on exam with lower extremity muscle edema on MRI; 2) Proximal muscle
weakness with elevation in CK, AST, aldolase, or LDH muscle enzymes; or 3) Patient reported weakness or muscle
pain and an elevated CK. Inflammatory myositis was present as a feature of SLE in 31% (n = 17) with a 95%
confidence interval of 19-45%, statistically different from the reported rates of 4-16% (p < 0.0001). Myositis was
positively associated with the presence of anti-ribonucleoprotein antibodies (p = 0.009). Negative associations with
myositis were the presence of anti-double stranded DNA antibodies (p = 0.02) and hematologic disorders (p =
0.02). Thus, in the state of Alabama, pediatric SLE myositis is present at a statistically higher rate than previously
published values of adult SLE myositis, possibly reflecting geographic (genetic or environmental) and/or age-of-
onset related influence(s).
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Introduction
Systemic lupus erythematosus (SLE) is a multisystem
autoimmune disease that is extremely heterogeneous in
both its clinical and serological presentation. SLE has
significant overlapping features of other conditions of
similar etiology, including mixed connective tissue dis-
ease (MCTD) and Sjögren syndrome. In order to distin-
guish SLE clinically from such entities, the American
College of Rheumatology (ACR) has set forth eleven
classification criteria (revised in 1997), of which the
patient must have four in order to be classified with
SLE [1]. The criteria are both highly sensitive and speci-
fic for SLE, though there are still significant discrepan-
cies in the literature with regard to classifying these
conditions when overlapping symptoms and serologies
are present [2,3].
Although commonly thought of as a disease of middle
age, nearly 15% of SLE presents in patients under the
age of 16. Additionally, the presenting features in chil-
dren are often more severe than in adults, and these
children have been shown to be twice as likely to
require higher dose corticosteroids [4-6]. Though not an
ACR classification criterion, myositis has traditionally
been recognized as a feature in of 4-16% of adult
patients with SLE [7-12]. The prevalence of myositis in
pediatric patients with SLE is not reported in these stu-
dies. In a small percentage of patients, myositis can
actually be the predominant presenting feature [9]. Clin-
ical features of myositis include proximal weakness,
myalgia, and muscle atrophy [13,14]. Patients with myo-
sitis generally have elevated serum creatine kinase (CK)
levels, proximal muscle inflammation by MRI, and
abnormal muscle biopsies. In patients with juvenile der-
matomyositis, 3-10% also have another autoimmune dis-
ease, the most common of which is scleroderma [15,16].
In one study, children with overlap myositis syndromes
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ter treatment response [17], whereas other data from
adult cohorts suggests that myositis overlap is more
severe and associated with higher mortality [18].
Symptoms that have been shown to correlate with
myositis in SLE patients include Raynaud phenomenon,
anemia, alopecia, oral ulcers, erosive joint disease, and
Sjögren syndrome [9,18,19]. These patients have also
been shown to less likely have lupus nephritis, though
this finding was not found to be statistically significant
[18]. Immunologically, anti-RNP antibodies have been
shown to be more likely in the myositis group [18]. The
aim of this study was to determine the prevalence of
clinically evident myositis in pediatric lupus patients in
a cohort of 55 patients from a single tertiary care center
in the state of Alabama and to compare it with the
reported prevalence of 4-16%. The widely accepted
Bohan and Peter criteria for myositis are dependent
upon muscle biopsy and electromyography results, both
of which are invasive and painful procedures not routi-
nely conducted in our practice. Therefore, clinical and
laboratory definitions of myositis were established. We
also determined the demographic, clinical, serological,
and laboratory features associated with lupus myositis in
this cohort and compare them with established associa-
tions in the adult population.
Materials and methods
Patient selection
The records of all patients seen after January 1, 2008 at
the Children’s Hospital of Alabama (CHA) with the
ICD-9 code of SLE on their electronic medical records
(n = 98) were identified. Of these 98 patients, 25 were
excluded because they had not been evaluated by the
Division of Pediatric Rheumatology at CHA and did not
have sufficient data to assess the presence of muscle
involvement, 2 because they had drug induced lupus,
and 16 because they either did not satisfy at least 4 out
of 11 ACR criteria for the classification of SLE [1] or
there was insufficient data available to make such a
determination. The 25 patients excluded that were not
evaluated by pediatric rheumatology were similar in
makeup to the final cohort, except for that they all had
renal manifestations of their SLE and were being fol-
lowed by pediatric nephrologists. The remaining 55
patients were included in these analyses. General demo-
graphic data collected included the following: 1) age of
onset of the first manifestations of SLE; 2) race/ethni-
city, defined as white, black, Hispanic, or Asian; and 3)
sex. Electronic medical records were retrospectively
reviewed and data was collected in a standard electronic
form. Institutional review board approval was obtained
prior to data collection.
Laboratory data
Lab values analyzed were complement component 3
(C3), complement component 4 (C4), total hemolytic
complement (CH50), creatine kinase (CK), lactate dehy-
drogenase (LDH), aldolase, alanine aminotransferase
(ALT), aspartate aminotransferase (AST), and g-glutamyl
transpeptidase (GGT). The lowest level of C3, C4, and
CH50 from the available laboratory data was recorded,
and it was noted whether this value was considered to
be low, normal, or high according to the reference range
from the laboratory performing the test. For the
enzymes analyzed (CK, LDH, aldolase, ALT, AST, and
GGT) the highest level from the available data was
recorded, and it was similarly noted whether this value
was considered low, normal, or high.
Antibody profile
The presence of the following antibodies was deter-
mined: anti-nuclear antibodies (ANA), ANA pattern,
anti-Smith antibodies (Sm), anti-double-stranded DNA
antibodies (dsDNA), U1-sn ribonucleoprotein antibodies
(RNP), scleroderma-70 antibodies (Scl-70), Ro/SS-A, La/
SS-B, rheumatoid factor (RF), lupus anticoagulant (LA),
b2-glycoprotein I antibodies (IgM and IgG only), and
anticardiolipin (aCL) antibodies (IgM and IgG only).
Patients were considered positive if their laboratory data
showed elevated titers of these antibodies compared to
the lab’s reference range at any point in time. In addi-
tion, it was noted whether the patient had a reactive
rapid plasma reagin (RPR), or if a partial thromboplastin
time (PTT) was increased on at least two occasions.
Other SLE features
The presence of any of the 9 ACR SLE clinical diagnos-
tic classification criteria was recorded. In addition, the
presence of alopecia, Raynaud phenomena, hypothyroid-
ism, and headaches were documented.
Definition of myositis
The Bohan and Peter criteria are the gold standard for
defining myositis, more specifically dermatomyositis, in
the literature. These criteria require muscle biopsy and
EMG [20,21] which are invasive and painful procedures
not routinely done in our practice, so at best, patients in
our cohort could only be described as having probable
polymyositis. Additionally, most centers do not use this
definition when describing patients with established SLE
or MCTD. Therefore, we established clinical and labora-
tory based definitions for this study. Patient histories
were reviewed for complaints of muscle weakness and
muscle pain. Physical exam notes were reviewed for
muscle strength testing. For the purpose of this study,
patients were defined as having myositis if they satisfied
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course of their disease:
1. Proximal muscle weakness on physical exam with
evidence of muscle edema on MRI [T2 or Short T1
Inversion Recovery (STIR)] images of the lower
extremity
2. Proximal muscle weakness on physical exam with
an elevation in one of the following muscle enzymes:
CK, AST, aldolase, or LDH
3. Patient reported muscle weakness or muscle pain
(without weakness noted on physical exam) and an
elevated CK
Statistical analysis
The proportion of lupus patients with myositis in this
cohort was determined and the Clopper-Pearson exact
binomial 95% confidence interval was calculated. The
prevalence rate of myositis in the cohort was compared
to previously published rates of myositis using the chi-
square test. Associations between myositis and the pre-
sence of clinical and laboratory factors were examined
using Fisher’s exact test, Wilcoxon rank-sum test, and
one-way ANOVA where appropriate. Statistical analyses
were performed using STATA 10.0 (StataCorp, College
Station, TX, USA).
Results
The mean age of our cohort at the time of this study
was 16 years (range, 9 to 21 years). The mean age at
onset of symptoms attributable to SLE was 13 ± 3 years
(range, 3 to 18 years), 87.3% were female, and 74.5%
were African-American. All 55 patients in the cohort
were ANA positive. There was a high prevalence of
anti-Sm antibodies in our cohort, with 69% of the entire
cohort having a positive Sm antibody.
Myositis was present as a feature of SLE in 31% (n =
17) with a 95% confidence interval of 19 to 45%. In the
myositis portion of the cohort, 13 (76%) of were female,
14 (82%) were African-American, and the mean age at
initial diagnosis of SLE was 13.1 ± 3.9 years old. This
data was not statistically different from the non-myositis
portion of the cohort. The mean age of diagnosis of
lupus myositis was 14 ± 4 years (range, 8 to 18 years),
which was on average 1.4 years after the initial SLE
diagnosis with 8 of 17 patients (47%) presenting with
myositis at their initial SLE diagnosis. SLE activity at
time of myositis diagnosis was assessed by the physician
global assessment score which was available for 9 of the
17 myositis patients. For these 9 patients, the average
physician global assessment score was 47 with a range
of 8 to 70, with < 5 being correlating with disease remis-
sion and 100 being the maximum amount of disease
activity. The proportion of children with myositis in our
cohort was significantly higher than each of the 6 pre-
viously reported SLE cohorts [7-12] (p < 0.05 for all
comparisons, ranging from p < 0.0001 to p < 0.047). If
all patients from these previously reported cohorts are
combined, the resultant prevalence of 7.6% (95% CI
6.1%-9.2%) is much lower than was present in our
cohort (p < 0.0001). Of these patients with myositis, 2
patients had weakness on physical exam and evidence of
muscle of edema on MRI, 12 patients had weakness on
physical exam with an elevation in CK, AST, aldolase,
and/or LDH, and 3 patients had self-reported muscle
pain or weakness with an elevated CK. If the 3 patients
in the latter category with subjective muscle pain or
weakness are excluded, the rate of myositis in our SLE
cohort becomes 26.9% which remains statistically higher
than the reported rate of 4-16%. Only 2 patients in the
cohort had MRI testing conducted. With the exception
of 1 patient in the cohort, their muscular symptoms
were typically mild. This cohort of pediatric SLE
patients all met formal SLE criteria but those with myo-
sitis shared features with MCTD, with 3 of the lupus
myositis patients meeting the Kusukawa criteria (RNP,
Raynaud or swollen fingers, and 1 or more findings con-
sistent with lupus, scleroderma, and/or polymyositis) for
MCTD [3], and none of the non-myositis cohort met
these MCTD criteria. Moreover, if the three patients
meeting MCTD criteria are excluded from the analysis,
then 26.9% of our SLE cohort had myositis, which
remains statistically higher than the reported rate of
4-16%.
The high prevalence of myositis among this pediatric
SLE cohort suggested there may be unique disease fea-
tures associated with the presence of myositis. There
were no obvious statistically significant demographic dif-
ferences in those with and without myositis, at least at
the level of statistical power afforded by the size of the
patient cohort.
Next, the clinical SLE features in the myositis and
non-myositis groups were compared and are summar-
ized in Table 1. Skin involvement (malar or discoid
rash) and hematologic disorders occurred less frequently
in the myositis group; of these, only the negative asso-
ciation with hematologic disorders (Coombs positive
hemolytic anemia, thrombocytopenia, neutropenia, or
lymphopenia) was determined to be statistically signifi-
cant (p = 0.02).
In addition to clinical criteria, immunologic criteria
were compared between the myositis and non-myositis
subgroups of SLE patients. The main hematologic and
immunologic features of SLE in the myositis and non-
myositis group are summarized in Table 2. Patients with
myositis were more likely to be RNP (p = 0.009) and
Sm (p = 0.06) positive, and less likely to be dsDNA
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cally significant, myositis patients were less likely to
have hypocomplementemia (low C3, C4 or CH50)
which correlates with the finding that they were also
less likely to have renal involvement (Table 1). Some of
the immunologic associations with myositis (presence of
RNP and speckled ANA pattern and absence of dsDNA)
were more reminiscent of MCTD than SLE. Thus,
although all the patients met formal ACR classification
criteria for SLE, those with myositis shared features of
MCTD.
Discussion
This study analyzed the prevalence and associated char-
acteristics of inflammatory myositis in a cohort of SLE
patients from a single center in the state of Alabama
that follows all cases diagnosed within a large geo-
graphic referral area. All patients met ≥ 4o ft h e1 9 9 7
revised ACR criteria for SLE classification. Due to lack
of invasive testing, patients only met possible Bohan and
Peter myositis criteria, and, furthermore, these criteria
are not typically applied to patients with previously diag-
nosed SLE or MCTD in the literature. Therefore, the
authors felt it was more appropriate to designate clinical
and laboratory parameters for defining myositis in this
study, though this classification is not established nor
validated in the medical literature.
I n t e r e s t i n g l y ,t h e r ew a sas u r p r i s i n g l yh i g hp r e v a l e n c e
of clinical myositis (31%) among this lupus cohort. By
comparison, Font et al. reported 39 of 600 (6.5%) adult
SLE patients with myositis as a component, which was
shown to have statistically significant association with
the presence of Raynaud phenomenon, anemia, and
anti-RNP when compared to patients without muscle
Table 1 Clinical features in pediatric SLE according to
myositis status
Myositis
group, n (%)
Non-myositis
group, n (%)
Entire
cohort,
n (%)
Malar rash 5 (29) 19 (50) 24 (44)
Discoid rash 1 (5.9) 8 (21) 9 (16)
Photosensitivity 3 (18) 8 (21) 11 (20)
Oral ulcers 9 (53) 17 (45) 26 (47)
Arthritis 11 (65) 26 (68) 37 (67)
Serositis 6 (35) 10 (26) 16 (29)
Renal disorder 8 (47) 25 (66) 33 (60)
Neurological disorder 1 (5.9) 5 (13) 6 (11)
Hematologic disorder
a 5 (29) 25 (66) 30 (55)
Alopecia 5 (29) 9 (24) 14 (25)
Raynaud phenomenon 5 (29) 12 (32) 17 (31)
Hypothyroidism 1 (5.9) 3 (7.9) 4 (7.3)
Myositis group, n = 17; non-myositis group, n = 38; entire cohort, n = 55.
aStatistically significant inverse association with myositis (p = 0.02).
Table 2 Immunologic and hematologic features in pediatric SLE according to myositis status
Myositis group, n (%) Non-myositis group, n (%) Entire cohort,
n (%)
ANA 17 (100) 38 (100) 55 (100)
ANA pattern:
Speckled 11 (65) 19 (50) 30 (55)
Homogeneous 5 (29) 16 (42) 21 (38)
Nucleolar 1 (5.9) 0 (0) 1 (1.8)
Dual 0 (0) 3 (7.9) 3 (5.5)
Sm
a 15 (88) 21/35 (60) 36/52 (69)
dsDNA
b 10 (59) 34 (89) 44 (80)
RNP
c 16 (94) 20/35 (57) 36/52 (69)
Scl-70 0/16 (0) 1/27 (3.7) 1/43 (2.3)
Ro/SS-A 8 (47) 16/32 (50) 24/49 (49)
La/SS-B 5 (29) 7/32 (22) 12/49 (24)
RF 3/9 (33) 6/21 (29) 9/30 (30)
Low C3 4 (24) 15 (39) 19 (35)
Low C4 7 (41) 24 (63) 31 (56)
Low CH50 2/5 (40) 12/20 (60) 14/25 (56)
b2-glycoprotein I 3/14 (21) 4/30 (13) 7/44 (16)
aCL (IgG and/or IgM) 3/14 (21) 17/29 (59) 20/43 (47)
LA 2/13 (15) 7/32 (22) 9/45 (20)
Increased PTT 5/14 (36) 6/32 (19) 11/46 (24)
Reactive RPR 2/6 (33) 4/11 (36) 6/17 (35)
Myositis group, n = 17; non-myositis group, n = 38; entire cohort, n = 55.
aNear statistically significant direct association with myositis (p = 0.06).
bStatistically
significant inverse association with myositis (p = 0.02).
cStatistically significant direct association with myositis (p = 0.009).
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7 of 150 (5%) adult SLE patients with inflammatory
myositis [8], and Feinglass et al. reported muscle invol-
vement in 15 of 140 (11%) adult SLE patients [7];
neither publication determined any symptoms associated
with the presence of myositis. Tsokos et al. reported
that 18 of 228 (8%) analyzed had significant muscle
involvement; however, of the 11 with muscle biopsies,
none met histological criteria for inflammation [11].
Michet et al. demonstrated 2 patients with features of
SLE and polymyositis and 2 patients with features of
SLE, polymyositis, and scleroderma out of a cohort of
46 patients (9%) that included both patients with defi-
nite and probable SLE [12]. Fessel et al. showed 10 of
64 (16%) to have polymyositis, which was typically clini-
cally mild, but they did not report any associated symp-
toms [10]. The proportion of children with myositis in
our cohort was significantly higher than all prior
reports. Unpublished data from the 641 adult SLE
patients in the LUMINA cohort demonstrated 103
(16.1%) with myositis/muscle weakness attributable to
lupus. Muscle enzymes, EMGs or biopsies were not spe-
cifically reported (personal communication, Graciela
Alarcon, University of Alabama at Birmingham, July 14,
2011). These previously reported rates used for compari-
son, however, are all based on analysis of adult cohorts,
whereas our study is of a pediatric cohort with the aver-
age age of onset of first symptoms attributable to SLE
being 13 ± 3 years. Because no formal evaluation and
reporting of the prevalence of myositis in pediatric SLE
have been published previously, it is not currently possible
to perform a direct comparison with another geographical
area. However, anecdotally, the pediatric rheumatologists
involved in this study (TB and RQC) do not recall such a
high proportion of pediatric SLE patients having inflam-
matory myositis in northern California, the state of
Washington, or the Philadelphia, PA area.
It is important to note that muscle symptoms are
often attributed to accompanying steroid and antimalar-
ial therapy, and an invasive muscle biopsy is the only
way to formally rule out this etiology. Though this mod-
ality is certainly a possibility in our cohort, this is much
less common than inflammatory myositis in diseases
like juvenile dermatomyositis. Additionally, the lupus
patients’ abnormal muscle enzymes appeared to improve
with immunosuppressive therapy (including corticoster-
oids) which argues for inflammatory myopathy and
against drug-induced myopathy as the etiology of their
clinical symptoms.
It is interesting to note the significant overlapping fea-
tures the SLE myositis group has with MCTD. All but
one myositis patient was RNP positive, and 11 of 17
(65%) had a speckled ANA pattern, though the latter
association was not found to be statistically significant.
Both of these findings are strongly associated with
MCTD. There has been much debate in the literature
regarding classifying MCTD, with some even question-
ing whether it is actually a separate entity or just the
early presentation of a yet undifferentiated collagen vas-
cular disease [2,22,23]. There was a strong tendency in
our cohort for patients to be both RNP and Sm positive:
of the 36 RNP positive patients, 94% (34) were also Sm
positive, and of the 36 Sm positive patients, 94% (34)
were also RNP positive. This may reflect the nature of
the immunoassay used to detect the individual compo-
nents of the Sm/RNP complex and adds to the complex-
ity of distinguishing SLE from MCTD. In the context of
other research regarding associated features of myositis
overlap, our findings of the tendency of myositis overlap
patients to have anti-RNP positive, renal sparing SLE is
consistent with the current literature [18]. Additionally,
the rate of anti-Sm antibodies in our cohort was 69%,
which is quite high compared to the reported prevalence
of 30% in North America [24]. This could be secondary
to the fact that our population is largely African-Ameri-
can, and the literature demonstrates that anti-Sm anti-
bodies are known to be more prevalent in African-
Americans [24-26].
Our patients were less likely to have hematological
involvement, which is in contrast to the associated ane-
mia demonstrated by Font et al. [9]. Other associations
demonstrated by Dayal et al. were alopecia, oral ulcers,
erosive joint disease, and Sjögren syndrome [18]; these
were not demonstrated in our pediatric cohort.
In summary, in the state of Alabama, pediatric SLE
myositis is statistically more prevalent than previously
published values of adult SLE myositis. The positive
association of myositis with anti-RNP antibodies (as a
feature of MCTD) is consistent with the medical litera-
ture [27]. The presence of both anti-RNP and anti-Sm
antibodies further highlights the significant overlap SLE
has with other autoimmune diseases such as MCTD and
the challenges that come with appropriately classifying
and treating these overlap patients. Clinically, myositis
can serve as a warning sign for a potential SLE flare and
a marker of the effectiveness of treatment. Awareness of
myositis in SLE is important for disease management,
and based on the current study, myositis, particularly in
subtle forms (e.g., low level inflammation as noted by
serum enzymes), may be much more common in SLE
than previously noted.
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